Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Feng Wang, PhD, Graciela Nogueras González, Gautam Borthakur, MD, Guilin Tang, MD, Carlos E. Bueso-Ramos, MD PhD, Rashmi Kanagal-Shamanna, MD, Juliana Elisa Hidalgo Lopez, MD, Chong Zhao, Marcus Coyle, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Farhad Ravandi, MBBS, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Andrew Futreal, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 47.

https://doi.org/10.1182/blood.V130.Suppl_1.47.47

Published: 2017

Journal Articles

Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Naval Daver, MD, Guillermo Garcia-Manero, MD, Sreyashi Basu, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Elias J. Jabbour, MD, Sherry Pierce, BSN, BA, Jing Ning, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Carlos E Bueso-Ramos, MD PhD, Juliana Elisa Hidalgo Lopez, MD, Jorge Blando, DVM, James Allison, PhD, Hagop M. Kantarjian, MD, Padmanee Sharma, MD PhD

Blood (2016) 128 (22): 1641.

https://doi.org/10.1182/blood.V128.22.1641.1641

Published: 2016

Journal Articles

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Naval Daver, MD, Sreyashi Basu, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Elias J. Jabbour, MD, Stephany Hendrickson, RN, Sherry Pierce, BSN, BA, Jing Ning, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, Naveen Pemmaraju, MD, Carlos E Bueso-Ramos, MD PhD, Jorge Blando, DVM, Juliana Elisa Hidalgo Lopez, MD, James Allison, PhD, Hagop M. Kantarjian, MD, Padmanee Sharma, MD PhD

Blood (2016) 128 (22): 763.

https://doi.org/10.1182/blood.V128.22.763.763

Published: 2016

Journal Articles

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

May Daher, MD, Juliana Elisa Hidalgo Lopez, MD, Jasleen K. Randhawa, MD, Kausar Jabeen Jabbar, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Katherine P. Hearn, BSN, RN, Steven R. Reyes, MS, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2016) 128 (22): 3191.

https://doi.org/10.1182/blood.V128.22.3191.3191

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

Email alerts

ASH Publications

American Society of Hematology

Update search

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only